Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of care for resectable stage III melanoma

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients

Outcomes of clinico-radiologically advanced cancer (cT4b) of buccal mucosa: A retrospective analysis of 104 patients

War in Ukraine: Impacts on the Ukrainian cancer care system

War in Ukraine: Current and future impacts on the Romanian cancer care system

International Society of Paediatric Surgical Oncology (IPSO) surgical practice guidelines

KEYNOTE 564 update: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma

First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study.

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022

Update on the new EUSOMA quality indicators for breast cancer